Jasper Therapeutics

JSPR · NASDAQ

$0.4999+$0.0225 (+4.71%)TodayMarket closed · Oct 20, 5:34 PM ET

Prev close $0.4774

JSPR analyst rating

BuyConsensus of 6 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy3
Hold3
Underperform0
Sell0

12-month price target · 6 analysts

Average $8.93 (+1685.4% upside)

Low: $2.02
Now: $0.4999
High: $21.00

Upgrades and downgrades

The latest rating actions, newest first

JSPR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
William Blair	Oct 14, 2026	Initiates	Outperform	—	35%
Piper Sandler	Aug 12, 2026	Initiates	Overweight	$2.00	40%
TD Cowen	May 15, 2026	Downgrade	Buy → Hold	—	49%
RBC Capital	May 15, 2026	Maintains	Sector Perform	$4.00 → $3.00	49%
Evercore ISI Group	Apr 1, 2026	Maintains	Outperform	$12.00 → $7.00	42%
UBS	Mar 23, 2026	Initiates	Neutral	$1.50	45%
RBC Capital	Nov 11, 2025	Maintains	Sector Perform	$5.00 → $4.00	49%

The case for and against

Updated Mar 27, 2026

Bull case

Jasper Therapeutics Inc demonstrates a strong potential for growth through its innovative approaches in hematopoietic stem cell therapy, particularly with its ligand-blocking technology that could enhance safety and efficacy. The company reported a compelling clinical efficacy data with an 89% complete response (CR) rate observed in diverse dosing cohorts, indicating a significant improvement in patient outcomes. Additionally, the differentiation of their product, briquilimab, highlighted by its shorter half-life compared to competitors, further positions Jasper Therapeutics favorably within the biotechnology sector.

Bear case

Jasper Therapeutics is facing significant challenges that have adversely affected its stock, notably a ~5% decline attributed to the ongoing investigation into a faulty drug lot for briquilimab, which has also caused a pause in the ETESIAN trial for asthma. Additionally, the company raised $30 million through common stock and pre-funded warrants, indicating a need for further capital amidst operational setbacks. The analyst firm has subsequently revised their price target dramatically from $20 to $7, reflecting negative adjustments in their model linked to an updated diluted share count.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.